AbbVie to Acquire J&J-Backed Aliada Therapeutics for $1.4 Billion in Alzheimer's Focus

Oct 28, 2024, 01:52 PM

AbbVie Inc. announced on Monday that it will acquire Aliada Therapeutics, a privately held therapy developer, for $1.4 billion in cash. The acquisition is aimed at strengthening AbbVie's focus on Alzheimer's disease and its neuroscience pipeline. Aliada Therapeutics, a J&J-backed company, is known for its lead compound ALIA-1758 and its novel blood-brain barrier technology, which are expected to enhance AbbVie's capabilities in developing treatments for neurodegenerative diseases. This deal, involving a Phase 1 biotech, marks AbbVie's third acquisition of the year and underscores its commitment to expanding its research and development in the central nervous system (CNS) domain.